| Literature DB >> 28007297 |
Marcello Marino1, Gabriele Crimi2, Sergio Leonardi3, Marco Ferlini2, Alessandra Repetto2, Rita Camporotondo4, Andrea Demarchi5, Ilaria De Pascali5, Francesca Falcinella5, Luigi Oltrona Visconti2, Stefano De Servi5, Maurizio Ferrario2, Gaetano Maria De Ferrari6, Massimiliano Gnecchi7.
Abstract
The management of noninfarct-related arteries in patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD) is still debated. We evaluated the prognostic impact of staged complete revascularization with percutaneous coronary intervention (PCI) in STEMI patients with MVD admitted to our hospital from 2005 to 2013. Patients undergoing staged complete revascularization (n = 300) were compared with 1:1 propensity score-matched patients with culprit lesion-only treatment (n = 300). We considered a composite primary end point of all-cause death, myocardial infarction, and urgent PCI. Secondary end points included components of the primary, cardiovascular death, any PCI excluding staged PCI. We also performed an analysis including only patients surviving at least 5 days. The median follow-up was 553 days. The primary end point occurred in 10.3% of patients in the staged complete revascularization group and in 16.3% of patients in the culprit lesion-only group (hazard ratio 0.61, 95% CI 0.38 to 0.95, p = 0.031). Although this difference was no longer significant when considering only the survivors at day 5, all-cause and cardiovascular mortalities were still reduced in the staged complete revascularization group. Complete revascularization was associated with a better outcome (hazard ratio 0.35, 95% CI 0.17 to 0.63, p = 0.005) if performed within 30 days of STEMI. In conclusion, compared with culprit lesion-only revascularization, in STEMI patients with MVD undergoing primary PCI, an approach of staged complete revascularization was associated with a better outcome.Entities:
Mesh:
Year: 2016 PMID: 28007297 DOI: 10.1016/j.amjcard.2016.10.040
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778